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Abstract
Background: Effective use of microbiology test results may positively influence patient outcomes and limit the use
of broad-spectrum antibiotics. However, studies indicate that their potential is not fully utilized. We investigated
microbiology test ordering practices and the use of test results for antibiotic decision-making in hospitals.
Methods: A multicentre cohort study was conducted during five months in 2014 in Medical departments across
three hospitals in Western Norway. Patients treated with antibiotics for sepsis, urinary tract infections, skin and soft
tissue infections, lower respiratory tract infections or acute exacerbations of chronic obstructive pulmonary disease
were included in the analysis. Primary outcome measures were degree of microbiology test ordering, compliance
with microbiology testing recommendations in the national antibiotic guideline and proportion of microbiology
test results used to inform antibiotic treatment. Data was obtained from electronic- and paper medical records and
charts and laboratory information systems.
Results: Of the 1731 patient admissions during the study period, mean compliance with microbiology testing
recommendations in the antibiotic guideline was 89%, ranging from 81% in patients with acute exacerbations of
chronic obstructive pulmonary disease to 95% in patients with sepsis. Substantial additional testing was performed
beyond the recommendations with 298/606 (49%) of patients with lower respiratory tract infections having urine
cultures and 42/194 (22%) of patients with urinary tract infections having respiratory tests. Microbiology test results
from one of the hospitals showed that 18% (120/672) of patient admissions had applicable test results, but only half
of them were used for therapy guidance, i.e. in total, 9% (63/672) of patient admissions had test results informing
prescription of antibiotic therapy.
Conclusions: This study showed that despite a large number of microbiology test orders, only a limited number of
tests informed antibiotic treatment. To ensure that microbiology tests are used optimally, there is a need to review
the utility of existing microbiology tests, test ordering practices and use of test results through a more targeted and
overarching approach.
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Background
Effective use of microbiology test results has been shown
to influence patient outcomes, health care costs and ap-
propriateness of antibiotic prescribing and – use [1–3].
Microbiology tests have also for years provided anti-
microbial resistance (AMR) surveillance data, informing
empiric antibiotic therapy guidelines. With increasing
AMR rates globally, sensitive, specific and affordable
microbiology tests could be important tools in providing
targeted antibiotic treatment to patients. The tests may
facilitate de-escalation of antibiotic therapy from broad-
to narrow spectrum treatment, thereby limiting the se-
lection of drug resistant bacteria.
However, several studies indicate that the potential of
microbiology tests is not fully utilized. Firstly, clinicians
feel they cannot make full use of microbiology tests due
to prolonged turnaround times (TATs) [4, 5]. Secondly,
although many guidelines provide microbiology test or-
dering recommendations and information on how to in-
terpret and use test results [6, 7], studies show that
microbiology test ordering and use of test results are
substandard [8–11]. As diagnostic microbiology methods
evolve and become more sophisticated, these inadequa-
cies may increase and ultimately result in incorrect anti-
biotic treatment for patients, as well as inefficient use of
human and laboratory resources [12].
There are some studies on yield and utility of blood cul-
tures, skin and soft tissue (SST) cultures, urinary pneumo-
coccal antigen (UPAg) and polymerase chain reaction
(PCR) tests detecting respiratory pathogens, and evidence
exists for excessive ordering of urine cultures in asymp-
tomatic patients [13–17]. However, there is little know-
ledge on existing microbiology test ordering practices and
clinical use of microbiology test results, which is needed to
optimize use of the tests. The aim of our study was there-
fore to investigate microbiology test ordering practices in
hospitals and how microbiology test results were used to
inform antibiotic decision-making. Our hypotheses were
that a majority of current microbiology test ordering prac-
tices did not adhere to recommendations in the national
antibiotic guideline and that a minority of microbiology
test results were used to guide antibiotic treatment.
Methods
Design, setting and study population
This study was a multicentre cohort study conducted in
infectious diseases-, gastroenterology- and pulmonary
medicine wards across three emergency care and teach-
ing hospitals in Western Norway. Patient data were ori-
ginally collected for a multicentre cluster randomized
controlled intervention study, evaluating antibiotic stew-
ardship interventions in hospital settings [18].
Hospital A and B were tertiary care hospitals with
1100 and 600 beds, respectively, offering a full range of
microbiology testing services. Hospital C was a second-
ary care hospital with 160 beds, referring the majority of
microbiology specimens to hospital A. Infectious dis-
eases- and pulmonary medicine wards were selected as
these specialties have the highest consumption of antibi-
otics and thus order a large proportion of microbiology
tests. Gastroenterology was included since hospital B
had a joint medication storage area for the pulmonary
medicine- and gastroenterology wards.
Microbiology test ordering practices were analysed
using data from patients discharged from the study wards
between February 10th and July 11th 2014. Only data
from patients receiving antibiotic treatment for sepsis,
urinary tract infections (UTIs), skin and soft tissue infec-
tions (SSTIs), lower respiratory tract infections (LRTIs) or
acute exacerbations of chronic obstructive pulmonary dis-
ease (AECOPD) was included in the analyses. Patients ad-
mitted for < 24 h, > 21 days and/or readmitted within 30
days were excluded. Clinical use of test results was ana-
lysed for patients at hospital A, as complete microbiology
test results were available at this hospital.
Outcome measures
The primary outcome measures were microbiology test
ordering practices and clinical use of microbiology test
results. The secondary outcome measures were yield and
TAT for the microbiology tests (Table 1).
Data collection
Patient data, including indication for antibiotic treat-
ment, antibiotic treatment throughout the hospital
stay, allergic reactions to antibiotics, glomerular filtra-
tion rate and number of days admitted were obtained
from medical records and drug charts. Indications for
antibiotic treatment were based on the treating physi-
cians’ working diagnoses as recorded in patients’
medical records or drug charts on the day of initi-
ation of antibiotic treatment. Laboratory data were
collected from medical records to evaluate microbiol-
ogy test ordering practices and yield, and from the la-
boratory information system to study clinical use of
microbiology test results and TAT (Table 1). An over-
view of microbiology tests and test results are pre-
sented in Table 2. Bacterial cultures were identified
by matrix assisted laser desorption ionization-time of
light mass spectrometry (Maldi-Tof MS) and suscepti-
bility testing was performed by disk diffusion tests or
by minimum inhibitory concentration gradient tests.
The PCR tests were developed in-house and the
UPAg test was a lateral flow immunoassay.
Data analysis
Descriptive statistical analyses were performed on all
outcome measures (Table 1). Chi-square test was
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applied to evaluate differences in microbiology testing
practices between the hospitals, where the testing fre-
quencies of each hospital were compared to the total test
frequency of the two others. Fisher’s exact test was applied
when numbers in one or more categories were < 5. Tests
were two-sided and because of multiple testing, p-values
< 0.01 were considered statistically significant. Statistical
analyses were performed using the SPSS (Statistical Pack-
age for the Social Science) version 24.
Results
In total, 1731 patient admissions were included in the
analyses of microbiology test ordering practices. The
mean age was 68 years old (range 15–103 years), the
female/male ratio was 0.48/0.52, mean length of stay
was 6.8 days and the 30 day-mortality rate was 8%
(142/1731). The distribution of diagnoses was as
follows: LRTI 35%, AECOPD 24%, sepsis 18%, SSTI
12% and UTI 11% (Table 3). Of the total patient co-
hort, 48% were recruited from Hospital A, 27% from
Hospital B and 25% from Hospital C.
Guideline adherence
The degree of compliance with microbiology test order-
ing recommendations in the national antibiotic guideline
was 89% across all diagnoses. Compliance was 95% in
sepsis (blood culture), 92% in UTI (urine culture), 88%
in LRTI (PCR test detecting respiratory pathogens,
UPAg test, respiratory- or blood culture) and 81% in
AECOPD (respiratory- and/or blood culture). There
were no specific test ordering recommendations for
SSTIs, however culture specimens were often obtained
from the site of infection.
Testing practices by tests, diagnoses and hospital sites
Many patients had more than one microbiology sam-
ple collected regardless of diagnosis (Table 3). In the
total cohort of patient admissions, the following
microbiology tests were ordered: 76% blood cultures,
54% urine cultures, 49% respiratory tests and 9% skin
or soft tissue cultures. Among the patients with LRTI
and AECOPD, 49 and 41% had urine cultures taken,
respectively. Concomitantly, 22% of the patients with
UTI had respiratory tests performed. Test ordering
practices varied between the three hospitals. Patients
diagnosed with sepsis, LRTI and AECOPD had sig-
nificantly more respiratory tests taken at hospital B
than at the two other hospitals (p < 0.01), and the
same groups of patients had significantly less respira-
tory tests taken at hospital C compared to the two
other hospitals (p < 0.01).






a. Degree of compliance with test ordering recommendations in the Norwegian national antibiotic guideline,
by diagnoses [6].
b. Degree of microbiology test ordering, i.e. the proportion of patients who had different specimens obtained within
the first three days after initiation of antibiotic treatment, by diagnoses and hospital sites
2: Clinical use of microbiology
test results
The proportion of microbiology tests ordered on the day of admission used to guide antibiotic treatment. Use was
assessed within the first two days after tests results were available to clinicians.
For an antibiotic regime to be defined as adjusted in accordance with microbiology test result, it had to be susceptible to
the identified pathogen and the regime least prone to drive antibiotic resistance. The evaluation took into account
glomerular filtration rate and allergic reactions to antibiotics as recorded on admittance.
Secondary outcomes
1: Yield of microbiology tests The proportion of patients for which a specific test
was positive and identified the potential causative pathogen. Reported by test and diagnoses.
2: Turnaround time for
microbiology tests
Time in hours from the specimen was registered as received at the laboratories to final test results were available to clinicians
in the electronic medical record. For blood cultures; time when gram stain results were made available to clinicians.
Table 2 Overview of microbiology tests and test results
Microbiology tests
Respiratory tests Respiratory cultures
Polymerase chain reaction (PCR) tests for viral and
bacterial respiratory pathogens
Urinary pneumococcal antigen tests
Skin and soft
tissue cultures




Positive findings Potential pathogen identified
a) Causative
findings
Positive test results identifying causative pathogen
b) Non-causative
findings
Positive test results reported as “contaminants”,
“normal flora” or “mixed flora”
Negative findings No pathogen identified
Skodvin et al. Antimicrobial Resistance and Infection Control            (2019) 8:28 Page 3 of 8
Yield
The total yield for blood-, urine-, respiratory- and SSTI
cultures was 8, 29, 34 and 67%, respectively (Table 4).
For blood cultures, the yield was 20% in sepsis- and 4%
in LRTI patients. For LRTI patients, the yield of the PCR
test detecting respiratory pathogens, UPAg test and re-
spiratory cultures was 18, 9 and 33%, respectively. How-
ever, 52% of the respiratory cultures had non-causative
findings.
Turnaround time
Mean TAT was 25 h (95% CI, 22.4–27.7) for blood-, 37 h
(95% CI, 31.2–42.6) for urine-, 56 h (95% CI, 49.5–63.0)
for SST- and 80 h (95% CI, 60.5–99.6) for respiratory
cultures.
Clinical use of test results
In hospital A, there were 828 patient admissions, of which
81 collected microbiology specimens at day > 1 after admis-
sion, leaving 747 cases eligible for inclusion in the analyses
of clinical use of microbiology test results obtained on the
day of admission. Of these, 672 (81%) had blood-, urine-,
respiratory- and/or SST cultures taken and were included
in the analyses of clinical use of test results (Fig. 1).
Of the 672 patient admissions, 358 (53%) had nega-
tive microbiology test results and 129 (19%) had non-
causative findings. Among the remaining 185 cases, 37
had findings not relevant to their diagnoses, four had
stopped antibiotic treatment and 24 were discharged
when microbiology test results became available. Of the
120/672 (18%) inpatients with applicable findings, anti-
biotic treatment was adjusted according to test results
only in 63 patients, i.e. 9% of the total number of pa-
tient admissions. Among the patients with the diagno-
ses SSTI and UTI, a majority had their antibiotic
treatment adjusted in accordance with the test results,
whereas treatment was adjusted only in a minority of
the patients with AECOPD. As only 120 patient admis-
sions had applicable test results, the number in each
diagnostic group was low.
Table 3 Microbiology test ordering practices
Microbiology test
Blood culture Urine culture SST culture1 Resp. test2
Diagnosis* Hospital % p3 % p3 % p3 % p3
Sepsis Hospital A n = 205 95.1 0.64 70.2 0.02 10.7 < 0.01 60.0 < 0.01
Hospital B n = 42 88.1 0.06 76.2 0.81 2.4 0.34 78.6 < 0.01
Hospital C n = 73 97.3 0.38 86.3 0.01 1.4 0.02 17.8 < 0.01
Total n = 320 94.7 74.7 52.8 7.5
UTI Hospital A n = 67 59.7 0.77 91.0 0.64 3.0 0.27 31.3 0.02
Hospital B n = 50 70.0 0.05 90.0 0.54 2.0 1.00 36.0 < 0.01
Hospital C n = 77 49.4 0.04 94.8 0.28 0.0 0.28 3.9 < 0.01
Total n = 194 58.2 92.3 1.5 21.6
SSTI Hospital A n = 97 80.4 0.97 14.4 < 0,01 68.0 < 0.01 8.2 0.66
Hospital B n = 54 79.6 0.89 13.0 0.04 44.4 0.16 11.1 0.22
Hospital C n = 52 80.8 0.92 50.0 < 0,01 32.7 < 0.01 1.9 0.12
Total n = 203 80.3 23.2 52.7 7.4
LRTI Hospital A n = 287 80.8 0.07 48.4 0.73 1.0 0.51 68.3 < 0.01
Hospital B n = 164 75.0 0.36 40.2 0.01 1.8 0.71 89.0 < 0.01
Hospital C n = 155 74.2 0.25 60.0 < 0,01 1.9 0.70 20.0 < 0.01
Total n = 606 77.6 49.2 1.5 61.6
AECOPD Hospital A n = 172 74.4 < 0.01 38.4 0.42 2.3 0.46 59.3 0.29
Hospital B n = 152 57.9 0.01 33.6 0.02 1.3 1.00 92.1 < 0.01
Hospital C n = 84 63.1 0.54 58.3 < 0.01 1.2 1.00 14.3 < 0.01
Total n = 408 65.9 40.7 1.7 62.3
All Total n = 1731 76.1 53.7 8.7 49.3
*AECOPD: acute exacerbation of chronic obstructive pulmonary disease; LRTI: lower respiratory infection; SSTI: skin and soft tissue infection; UTI: urinary tract infection
1SST culture: wound, pus, breastmilk or tissue culture
2Resp. test: respiratory culture, polymerase chain reaction (PCR) test for viral and bacterial respiratory pathogens and/or urinary pneumococcal antigen test
3p value for testing whether there is a significant difference between one hospital compared to the total frequencies of the two others by Chi-square test or by
Fisher’s exact test when numbers in one or more categories were < 5
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Discussion
The main finding of this study was that despite a large
number of microbiology test orders, only a small frac-
tion of test results informed antibiotic decision-making.
We observed high compliance with test ordering recom-
mendations in the national guideline, but excessive test-
ing across diagnoses, contributing to a low yield. TATs
were long and microbiology test results with causative
pathogens were underused, both contributing to the low
utilization of the tests.
To our knowledge, this is the first study reporting
on microbiology test ordering practices and use of
test results in clinical practice. A previous study on
clinical laboratory- and imaging tests, reported that
one third of tests were unnecessary and only half of
relevant test results were used in patient follow up
[11]. Studies investigating the yield of blood culture
and UPAg tests, showed similar results to ours [13,
14, 19, 20]. The high rates of respiratory cultures with
non-causative findings identified in our material are
also in accordance with the literature, reporting that
respiratory sampling procedures are challenging [21].
Our study shows that the existing microbiology tests,
testing practices and use of test results are not in accord-
ance with the objective of microbiology testing; only a
minor fraction of patients benefitted from a test result and
only a small proportion could be used to target therapy
and minimize the use of broad spectrum antibiotics. This
suggests that microbiology laboratory resources could be
spent more efficiently than producing insignificant or nega-
tive results, although negative microbiology test results
may be important for treatment in some infectious disease
patients. Only half of the patients with test results identify-
ing the causative pathogen had their antibiotic treatment
tailored accordingly, meaning that antibiotic treatment was
not optimized for the other half of the patients.
There are several explanations for these findings. Exces-
sive testing and inadequate follow up of test results may
be caused by clinician’s insufficient knowledge of micro-
biology [22, 23]. Diagnostic uncertainty and inadequate
Table 4 Yield of microbiological specimen
Diagnosis* Test findings Blood culture % Urine culture % SST culture1% Respiratory culture % RP-PCR2 % UPAg3 %
Sepsis Causative 20 36 63 29 18 8
Non-causative 5 16 25 58
Negative 75 48 13 13 82 92
Total 100 (n = 303) 100 (n = 239) 100 (n = 24) 100 (n = 52) 100 (n = 106) 100 (n = 111)
UTI Causative 17 54 33 0 0 0
Non-causative 4 17 67 80
Negative 79 28 0 20 100 100
Total 100 (n = 113) 100 (n = 179) 100 (n = 3) 100 (n = 15) 100 (n = 27) 100 (n = 21)
SSTI Causative 4 30 70 40 0 0
Non-causative 4 15 23 60
Negative 92 55 7 0 100 100
Total 100 (n = 163) 100 (n = 47) 100 (n = 107) 100 (n = 5) 100 (n = 11) 100 (n = 4)
LRTI Causative 4 16 67 33 17 9
Non-causative 2 20 22 52
Negative 94 63 11 15 83 91
Total 100 (n = 470) 100 (n = 298) 100 (n = 9) 100 (n = 185) 100 (n = 240) 100 (n = 196)
AECOPD Causative 1 17 43 41 8 10
Non-causative 4 16 43 45
Negative 94 67 14 14 92 90
Total 100 (n = 269) 100 (n = 166) 100 (n = 7) 100 (n = 161) 100 (n = 167) 100 (n = 123)
Total Causative 8 29 67 34 13 8
Non-causative 4 18 25 51
Negative 88 53 8 14 87 92
Total 100 (n = 1318) 100 (n = 929) 100 (n = 150) 100 n = (418) 100 (n = 551) 100 (n = 455)
*AECOPD: acute exacerbation of chronic obstructive pulmonary disease; LRTI: lower respiratory infection; SSTI: skin and soft tissue infection; UTI: urinary tract infection
1SST culture: wound, pus, breastmilk or tissue culture; 2RP-PCR: Respiratory panel polymerase chain reaction test for viral and bacterial respiratory pathogens;
3UPAg: Urinary pneumococcal antigen tests
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routines for microbiology testing in the emergency depart-
ments may also contribute to the large number of un-
necessary test orders [24]. However, the inherent
characteristics of the microbiology tests play a major role
for the yield; although adhering to the guidelines when
sampling specimens, the yield for several tests was low.
However, in this study, we did not have information on
the quality of sampling and transportation of specimens,
which may also impact the yield [8, 25]. Long TATs associ-
ated with certain tests may reduce their utility. We ob-
served particularly long TAT for respiratory cultures. This
may partly be explained by the time-consuming challenge
of identifying and separating respiratory pathogens from
normal bacterial flora. One reason for the continuation of
these practices, both in the microbiology laboratories and
in the clinical units, may be a lack of communication be-
tween the two parties to improve microbiology testing
practices [23].
Our findings show the need for a systematic review of
the use of microbiology tests in clinical practice. Firstly,
tests with low yield should be evaluated, particularly
tests for respiratory infections as our and other studies
show that microbiology test results are of little help to
identify causative pathogens [14, 20, 21]. Thus, more
specific and sensitive tests in the diagnostic work up of
respiratory infections are needed. Secondly, there is a
need to review the indications for microbiology tests.
Obviously, restricting urine cultures to patients with
possible UTIs may reduce unnecessary antibiotic treat-
ment of asymptomatic bacteriuria [26]. Additionally, al-
though the overall yield for blood cultures was low in
our study, it varied significantly between patients
suffering from respiratory infections in the lower end
and sepsis patients in the higher end. This indicates that
a stratification, prioritizing blood cultures for the more
severely ill patients, may be appropriate and increase
overall yield.
Thirdly, there is a need to reduce TATs and increase
the proportion of microbiology test results available at
an early stage of patient treatment. Potential measures
are expansion of molecular diagnostics, rapid and
point-of-care test services, as well as revision of testing
processes within the microbiology laboratories, shown to
reduce TAT significantly [27, 28]. These measures, pro-
moting rapid delivery of microbiology test results with
better performance characteristics, are even more im-
portant in settings with higher rates of AMR than
Norway [29]; In such settings, the identification of
causative pathogens and their susceptibility to antibiotic
agents, is crucial for appropriate and targeted antibiotic
treatment. Furthermore, clinicians need to increase their
knowledge of different microbiology tests; when to order
them and how to apply the test results. Systematic mea-
sures such as providing education, audit with feedback
on microbiology test ordering and use of test results, as
well as establishing decision support for microbiology
testing in computerized provider order entry systems,
may be useful [30]. In order to accommodate all these
challenges adequately, there is a need for clinical- and
microbiology laboratory staff to work in partnership.
Moreover, to develop sustainable and efficient solutions,
there is a need for a targeted and overarching approach.
An improved utilisation of microbiology services is
vital both for the individual infectious disease patients in
Fig. 1 Patient admissions and use of microbiology test results
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need of optimised antibiotic therapy and for the contain-
ment of AMR. Microbiology tests can contribute to re-
duced use of broad spectrum antibiotics and antibiotics in
general, thereby limiting the impetus for development and
selection of drug resistant bacteria. With improved avail-
ability of microbiology test results and increased test accur-
acy, treatment can be more targeted and broad spectrum
antibiotics saved [31]. Additionally, rapid access to micro-
biology test results differentiating viral and bacterial infec-
tions, may reduce unnecessary use of antibiotics [32].
In summary, this study raises several questions regard-
ing the future of microbiology testing. How can we utilize
microbiology testing and the laboratory resources more
efficiently? Which diagnostic tests do we need to develop?
And how can we improve interdisciplinary collaboration
around the infectious disease patient? Thus, more re-
search is needed on how to optimize the collection of
microbiology samples, how to develop and implement
new diagnostic methods and how to reduce TAT for
microbiology tests, taking into account the potential im-
pact on patient outcomes, antibiotic prescribing and de-
velopment of AMR, as well as on use of human and
laboratory resources.
The study has some limitations. Microbiology test results
were mainly based on traditional culturing and Maldi-Tof
MS. Use of novel technology such as molecular diagnostics
could have decreased TAT and increased the proportion of
test results used to inform antibiotic treatment [27]. Patient
data used for analysis in this study were originally collected
for an interventional study on antibiotic prescribing in hos-
pitals [18]. However, we supplemented with microbiology
data to accommodate the needs of this study. Data collec-
tion was limited to departments of internal medicine in
Western Norway, potentially reducing the external validity.
This is however a relatively large, multicentre study, apply-
ing an extensive amount of different data and covering a
wide range of clinical scenarios.
Conclusion
This study identified high compliance with microbiol-
ogy testing recommendations in the national guide-
line. There was however extensive ordering of
additional tests, many tests had low yield and only a
small proportion of test results informed antibiotic
decision-making. This highlights that the current use
of microbiology laboratory services is suboptimal.
There is a need both for tests with better performance
characteristics and improved test ordering practices.
Furthermore, use of microbiology test results to in-
form antibiotic decision-making needs to be optimized
in order to ensure adequate patient treatment and
more targeted therapy. To fill these gaps there is a
need for an overarching approach with a clear call to
fulfil the objective of microbiology testing; to provide
rapid, sensitive test results to individual patients, but
also to facilitate prudent use of antibiotics.
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